- 3. Special items
- 4. Sales
- 5. Cost of sales
- 6. Cost of materials
- 7. Personnel expenses
- 8. Selling, general and administrative expenses
- 9. Net interest
- 10. Other financial result
- 11. Taxes
- 12. Earnings per share
11. Taxes
INCOME TAXES
Income before income taxes was attributable to the following geographic regions:
€ in millions | 2010 | 2009 |
---|---|---|
Germany | 338 | 342 |
International | 1,448 | 1,101 |
Total | 1,786 | 1,443 |
Income tax expenses (benefits) for 2010 and 2009 consisted of the following:
€ in millions | Current taxes | Deferred taxes | Income taxes |
---|---|---|---|
2009 | |||
Germany | 83 | - | 83 |
International | 358 | 11 | 369 |
Total | 441 | 11 | 452 |
2010 | |||
Germany | 97 | -10 | 87 |
International | 472 | 22 | 494 |
Total | 569 | 12 | 581 |
In 2010 and 2009, Fresenius SE (since January 28, 2011: Fresenius SE & Co. KGaA) was subject to German federal corporation income tax at a base rate of 15% plus a solidarity surcharge of 5.5% on federal corporation taxes payable.
A reconciliation between the expected and actual income tax expense is shown below. The expected corporate income tax expense is computed by applying the German corporation tax rate (including the solidarity surcharge) and the effective trade tax rate on income before income taxes. The respective combined tax rate was 29.0% for the fiscal years 2010 and 2009.
€ in millions | 2010 | 2009 |
---|---|---|
Computed "expected" income tax expense | 518 | 418 |
Increase (reduction) in income taxes resulting from: | ||
Items not recognized for tax purposes | 12 | 11 |
Tax rate differential | 63 | 54 |
Tax-free income | -23 | -32 |
Taxes for prior years | 9 | 19 |
Changes in valuation allowances on deferred tax assets | 24 | 5 |
Noncontrolling partnership interests | -20 | -19 |
Other | -2 | -4 |
Income tax | 581 | 452 |
Effective tax rate | 32.5% | 31.3% |
DEFERRED TAXES
The tax effects of the temporary differences that gave rise to deferred tax assets and liabilities at December 31 are presented below:
€ in millions | 2010 | 2009 |
---|---|---|
Deferred tax assets | ||
Accounts receivable | 29 | 33 |
Inventories | 65 | 54 |
Other current assets | 47 | 38 |
Other non-current assets | 84 | 54 |
Accrued expenses | 235 | 208 |
Other short-term liabilities | 88 | 61 |
Other liabilities | 37 | 39 |
Benefit obligations | 55 | 37 |
Losses carried forward from prior years | 145 | 124 |
Deferred tax assets, before valuation allowance | 785 | 648 |
less valuation allowance | 116 | 92 |
Deferred tax assets | 669 | 556 |
Deferred tax liabilities | ||
Accounts receivable | 12 | 10 |
Inventories | 15 | 13 |
Other current assets | 113 | 54 |
Other non-current assets | 511 | 486 |
Accrued expenses | 8 | 43 |
Other short-term liabilities | 53 | 7 |
Other liabilities | 27 | 14 |
Deferred tax liabilities | 739 | 627 |
Net deferred taxes | -70 | -71 |
In the consolidated statement of financial position, the net amounts of deferred tax assets and liabilities are included as follows:
2010 | 2009 | ||||
---|---|---|---|---|---|
€ in millions | thereof short-term |
thereof short-term |
|||
Deferred tax assets | 492 | 380 | 395 | 280 | |
Deferred tax liabilities | 562 | 74 | 466 | 51 | |
Net deferred taxes | -70 | 306 | -71 | 229 |
As of December 31, 2010, Fresenius Medical Care has not recognized a deferred tax liability on approximately €2.6 billion of undistributed earnings of its foreign subsidiaries, because those earnings are intended to be indefinitely reinvested.
NET OPERATING LOSSES
The expiration of net operating losses is as follows:
for the fiscal years | € in millions |
---|---|
2011 | 6 |
2012 | 14 |
2013 | 13 |
2014 | 20 |
2015 | 22 |
2016 | 29 |
2017 | 11 |
2018 | 10 |
2019 | 6 |
2020 and thereafter | 31 |
Total | 162 |
The total remaining operating losses of €263 million can mainly be carried forward for an unlimited period.
Based upon the level of historical taxable income and projections for future taxable income, the Management of the Fresenius Group believes it is more likely than not that the Fresenius Group will realize the benefits of these deductible differences, net of the existing valuation allowances, at December 31, 2010.
UNRECOGNIZED TAX BENEFITS
Fresenius SE & Co. KGaA and its subsidiaries are subject to tax audits on a regular basis.
In Germany, the tax audit for the years 1998 until 2001 has been finalized. All results of the completed tax audits are already sufficiently recognized in the consolidated financial statements as of December 31, 2008. The fiscal years 2002 to 2005 are currently under audit. As of December 31, 2010, all proposed adjustments have been recognized in the consolidated financial statements. All further fiscal years are open to tax audits. For the tax year 1997, Fresenius Medical Care recognized an impairment of one of its subsidiaries which the German tax authorities disallowed in 2003 at the conclusion of its audit for the years 1996 and 1997. Fresenius Medical Care has filed a complaint with the appropriate German court to challenge the tax authority’s decision. In January 2011, Fresenius Medical Care reached an agreement with the tax authorities, estimated to be slightly more favorable than the tax benefit recognized previously. The additional benefit will be recognized in 2011.
In the United States, Fresenius Medical Care filed claims for refunds contesting the Internal Revenue Service’s (IRS) disallowance of Fresenius Medical Care Holdings, Inc.’s (FMCH) civil settlement payment deductions taken by FMCH in prior year tax returns. As a result of a settlement agreement with the IRS, Fresenius Medical Care received a partial refund in September 2008 of US$37 million, inclusive of interest, and preserved the right to pursue claims in the United States Courts for refunds of all other disallowed deductions. On December 22, 2008, Fresenius Medical Care filed a complaint for complete refund in the United States District Court for the District of Massachusetts, styled as Fresenius Medical Care Holdings, Inc. v. United States. On June 24, 2010, the court denied FMCH’s motion for summary judgment and the litigation is proceeding towards trial. The unrecognized tax benefit relating to these deductions is included in the total unrecognized tax benefit noted below. The IRS tax audits of FMCH in the United States for the years 2002 through 2006 have been completed. The IRS has disallowed all deductions taken during these audit periods related to intercompany mandatorily redeemable preference shares. In addition, the IRS proposed other adjustments which have been recognized in the consolidated financial statements. Fresenius Medical Care has protested the disallowed deductions and will avail itself of all remedies. An adverse determination with respect to the disallowed deductions related to the intercompany mandatorily redeemable preference shares could have a material adverse effect on Fresenius Medical Care’s results of operations and liquidity. Fiscal years 2007 and 2008 are currently under audit, 2009 and 2010 are open to audit. There are a number of state audits in progress and various years are open to audit in other states. All expected results have been recognized in the consolidated financial statements.
Subsidiaries of Fresenius SE & Co. KGaA in a number of countries outside of Germany and the United States are also subject to tax audits. The Fresenius Group estimates that the tax effects of such audits are not material to the consolidated financial statements.
The following table shows the changes to unrecognized tax benefits during the year 2010:
€ in millions | 2010 |
---|---|
Balance at January 1, 2010 | 355 |
Increase in unrecognized tax benefits prior periods | 10 |
Decrease in unrecognized tax benefits prior periods | -15 |
Increase in unrecognized tax benefits current periods | 18 |
Changes related to settlements with tax authorities | -26 |
Foreign currency translation | 12 |
Balance at December 31, 2010 | 354 |
Included in the balance at December 31, 2010 are €354 million of unrecognized tax benefits, which would affect the effective tax rate if recognized. As a result of the settlement agreement for 1997 noted above, the Fresenius Group estimates that the unrecognized tax benefits at December 31, 2010 could be reduced by approximately US$196 million in 2011 with a small portion of the reduction being realized as an additional tax benefit in 2011. The Fresenius Group is currently not in a position to forecast the timing and magnitude of changes in other unrecognized tax benefits.
It is Fresenius Group’s policy to recognize interest and penalties related to its tax positions as income tax expense. During the fiscal year 2010, the Fresenius Group recognized €8 million in interest and penalties. The Fresenius Group had a total accrual of €43 million of tax related interest and penalties at December 31, 2010.
10. Other financial result
12. Earnings per share